Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963064 · ClinicalTrials.gov registry record · Phase 1
JSP191 Antibody Targeting Conditioning in SCID Patients
A Phase 1 study, sponsored by Jasper Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02963064 is a Phase 1 study that was terminated before completion, run by Jasper Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT02963064, a Phase 1 study, was terminated before completion, sponsored by Jasper Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation
Interventions
- BIOLOGICAL Humanized anti-CD117 Monoclonal Antibody (JSP191)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2025-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02963064
The ClinicalTrials.gov registry entry for NCT02963064 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jasper Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Humanized anti-CD117 Monoclonal Antibody (JSP191) is the first listed.
NCT02963064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02963064 about?
NCT02963064 is a clinical study titled "JSP191 Antibody Targeting Conditioning in SCID Patients". A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation
What is the current status of trial NCT02963064?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2017-03-20. Estimated completion is 2025-07-07.
What interventions are being tested in trial NCT02963064?
The interventions under investigation include: Humanized anti-CD117 Monoclonal Antibody (JSP191) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02963064?
This trial is sponsored by Jasper Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.